SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted

Manuela Mancini(Istituto Oncologico Romagnolo), Simona Soverini(University of Bologna)
Biomarker Research
March 9, 2023
10.1186/s40364-023-00468-7
Cited by 6

Related Papers

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
|Blood|2011|460
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
|Cancer Cell|2014|366
Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement
|Cancer|2013|143
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis
|Leukemia|2017|38
Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
|Cancers|2022|2